Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q2 2024 · 10-Q
Revenue$87.00M$87.00M+73.5% vs Q2 2023 Net Income$8.92M$8.92MN/M vs Q2 2023 EPS Diluted$0.31$0.31N/M vs Q2 2023 Operating Income$5,012,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$18,769,000N/M Margins · derivedOperating margin5.8%+48.0 pt vs Q2 2023
Net margin10.3%+47.7 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 5, 2024 · 36 d after period end